Nurix Therapeutics Announces Collaboration With Seagen To Develop A Portfolio Of Degrader-Antibody Conjugates; Co. To Receive $60M Upfront Payment And Potential For $3.4B In Milestones Plus Royalties
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics has announced a collaboration with Seagen to develop a portfolio of degrader-antibody conjugates. Nurix will receive a $60M upfront payment and has the potential to earn $3.4B in milestones, plus royalties.
September 07, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seagen has entered into a collaboration with Nurix Therapeutics to develop a portfolio of degrader-antibody conjugates.
While the collaboration with Nurix represents a strategic move for Seagen, the upfront payment of $60M and potential future payments could impact its short-term financial position. However, the long-term potential of the partnership could offset this.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Nurix Therapeutics has entered into a lucrative partnership with Seagen, which includes a $60M upfront payment and potential for $3.4B in milestones plus royalties.
The collaboration with Seagen provides Nurix with a significant upfront payment and the potential for substantial future revenues. This is likely to boost investor confidence and could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100